1. Ohno M, Takahashi M, Yanagisawa S, Osawa S, Tsuchiya T, Fujita S, Igaki H, Narita Y. Development of a scoring system to predict local recurrence in brain metastases following complete resection and observation. J Neurooncol. 2024.
2. Ozeki Y, Honda-Kitahara M, Yanagisawa S, Takahashi M, Ohno M, Miyakita Y, Kikuchi M, Nakano T, Hosoya T, Sugino H, Satomi K, Yoshida A, Igaki H, Kubo Y, Ichimura K, Suzuki H, Masutomi K, Kondo A, Narita Y. Early progressive disease within 2 years in isocitrate dehydrogenase (IDH)-mutant astrocytoma may indicate radiation necrosis. Jpn J Clin Oncol. 2025;55(2):106-12.
3. Tsuchiya T, Kawauchi D, Ohno M, Miyakita Y, Takahashi M, Yanagisawa S, Osawa S, Fujita S, Omura T, Narita Y. Risk Factors of Distant Recurrence and Dissemination of IDH Wild-Type Glioblastoma: A Single-Center Study and Meta-Analysis. Cancers (Basel). 2024;16(16).
4. Sakurada K, Sato I, Ikeda M, Narita Y. Mental health status and associated factors of caregivers of patients with malignant brain tumors. J Neurooncol. 2025.
5. Kanamori M, Tsuzuki S, Shibahara I, Saito K, Shimoda Y, Tanaka K, Yamaguchi S, Natsumeda M, Matsutani T, Hanihara M, Nakada M, Kuroda JI, Matsuda M, Yoshimoto K, Yonezawa U, Sonoda Y, Takano K, Yonezawa H, Otani Y, Nakahara Y, Uchida M, Nonaka M, Mineharu Y, Kitamura Y, Yamashita S, Yamauchi T, Miyake Y, Deguchi S, Beppu T, Tamura K, Koizumi S, Hirose Y, Asano K, Hiruta R, Kinoshita M, Miyake K, Nakayama N, Inoue A, Ono T, Sasaki T, Akiyama Y, Fukami S, Yoshino A, Kawanishi Y, Asanome T, Yamaguchi T, Takahashi M, Yamasaki F, Arakawa Y, Narita Y. Impact of tumor-treating fields on the survival of Japanese patients with newly diagnosed glioblastoma: A multicenter, retrospective cohort study. Neurooncol Adv. 2024;6(1):vdae176.
6. Ono T, Uto M, Mineharu Y, Arakawa Y, Nakamura M, Nishio T, Igaki H, Nihei K, Ishikura S, Narita Y, Mizowaki T, Group BTSGaRTSGotJCO. Dummy run study for outlining and plan quality of intensity-modulated radiotherapy in elderly patients with newly diagnosed glioblastoma: The Japan clinical oncology group study JCOG1910 (AgedGlio-PIII). Radiat Oncol. 2025;20(1):32.
7. Nakashima T, Yamamoto R, Ohno M, Sugino H, Takahashi M, Funakoshi Y, Nambu S, Uneda A, Yanagisawa S, Uzuka T, Arakawa Y, Hanaya R, Ishida J, Yoshimoto K, Saito R, Narita Y, Suzuki H. Development of a rapid and comprehensive genomic profiling test supporting diagnosis and research for gliomas. Brain Tumor Pathol. 2024;41(2):50-60.
8. Kinoshita M, Fushimi Y, Masumoto T, Sasaki K, Sekita T, Natsume A, Wakabashi T, Komori T, Tsuzuki S, Muragaki Y, Motomura K, Saito R, Sato K, Beppu T, Takahashi M, Kuroda JI, Sonoda Y, Kobayashi K, Mishima K, Mitsuya K, Yamasaki F, Inoue A, Matsutani T, Nakamura H, Yamaguchi S, Ishikawa E, Nakaya M, Tanaka S, Ujifuku K, Uchida H, Kanamori M, Otani R, Kijima N, Nishida N, Yoshino A, Mineharu Y, Arakawa Y, Fukuda H, Narita Y, (JCOG-BTSG) MoJCOGBTSG. Image-based Re-evaluation of the JCOG0911 Study Focusing on Tumor Volume and Survival, Disease Progression Diagnosis, and Radiomic Prognostication for Newly Diagnosed Glioblastoma. Magn Reson Med Sci. 2024.
9. Kawaguchi Y, Watanabe Y, Miyakita Y, Ohno M, Ogawa C, Takahashi M, Yanagisawa S, Mukai T, Igaki H, Sugino H, Yoshida A, Narita Y. Successful treatment of pediatric patients with high-grade gliomas featuring leptomeningeal metastases by targeting BRAF V600E mutations with dabrafenib plus trametinib: two illustrative cases. Int Cancer Conf J. 2024;13(3):256-62.
10. Nakagawa-Saito Y, Mitobe Y, Togashi K, Suzuki S, Sugai A, Takenouchi S, Nakamura K, Sonoda Y, Kitanaka C, Okada M. The MDM2-p53 Axis Represents a Therapeutic Vulnerability Unique to Glioma Stem Cells. Int J Mol Sci. 2024, 25, 3948, doi: 10.3390/ijms25073948.